Microbial pathogens and apoptotic anticancer therapy

Bibliography

• GREENTREE LB: Antibiotics and cancer: clue to cure med. Hypoth. (1983) 10:37–41.
   PubMed Web of Science ®Google Scholar
• CARDENAS ME, SANFRIDSON A, CUTLER NS, HEITMAN J: Signal-transduction cascades as targets for therapeutic intervention by natural products. TIBTECH (1998) 16:427–433.
   PubMed Web of Science ®Google Scholar
• LEVITSKY A: Signal transduction therapy. A novelapproach to disease management. Fur. J. Biochem. (1994) 226:1–13.
   Google Scholar
• DIVE C, EVANS CA, WETTON AD: Induction ofapoptosis-new targets for cancer chemotherapy. Cancer Biol. (1992) 3: 417–427.
   PubMedGoogle Scholar
• DIVE C, WYLLIE AH: Apoptosis and cancerchemotherapy. In: New Frontiers in Pharmacology. Hickman JA, Tritton TT (Eds.) Blackwell Science, London, UK (1992).
   Google Scholar
• GIBBS JB, OLIFF A: Pharmaceutical research in molecular oncology. Cell (1994) 79:193–198.
   PubMed Web of Science ®Google Scholar
• PARDOLL DM: Cancer vaccines. Immunol. Today (1993) 14:310–316.
   PubMedGoogle Scholar
• HORIG H, KAUFMAN HL: Current issues in cancer vaccine development. Clin. Immunol. (1999) 92:211–223.
   PubMed Web of Science ®Google Scholar
• FITZGERALD D, PASTAN I, ROBERTS J: Clinical applica-tions of immunotoxins. Introduction. Curr. Top. Micro biol. Immunol. (1998) 234:83–96.
   PubMed Web of Science ®Google Scholar
• SPRINGER CJ, NICULESCU-DUVAZ I: Antibody-directed enzyme prodrug therapy (ADEPT): a review. Adv. Drug Delivery Rev. (1997) 26:151–172.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J: Fighting cancer by attacking its blood supply. Sci. American (1996) Sept:116–119.
   Google Scholar
• TAN Y, XU M, GUO H, SUN X, KUBOTA T, HOFFMAN RM:Anticancer efficacy of methioninase in vivo. AntiCancer Res. (1996) 16:3931–3936.
   PubMed Web of Science ®Google Scholar
• MARTIN SJ, GREEN DR: Apoptosis as a goal of cancer therapy. Curr. opin. Oncol. (1994) 6:616–621.
   PubMedGoogle Scholar
• MCDONNELL TJ, MEYN RE, ROBERTSON LE: Implications of apoptotic cell death regulation in cancer therapy. Sem. Cancer Biol. (1995) 6:53–60.
   PubMed Web of Science ®Google Scholar
• WEINRAUCH Y, ZYCHLINSKY A: The induction of apoptosis by bacterial pathogens. Ann. Rev. Micro biol. (1999) 53:155–87.
   PubMed Web of Science ®Google Scholar
• •A very good and comprehensive review on bacterial pathogens and apoptosis.
   Google Scholar
• MOSS JE, ALIPRANTIS AO, ZYCHLINSKY A: The regula-tion of apoptosis by microbial pathogens. Int. Rev. Cytol. (1999) 187:203–259.
   PubMed Web of Science ®Google Scholar
• ZYCHLINSKY A, FITTIG J, CAVAILLON M, SANSONETTI PJ:Interleukin 1 is released by murine macrophages during apoptosis induced by Sbigella flexneri. J. Clin. Invest. (1994) 94:1328–1332.
   PubMed Web of Science ®Google Scholar
• CHEN Y, ZYCHLINSKY A: Apoptosis induced by bacterial pathogens. Microbiol. Pathol. (1994) 17:203–212.
   PubMed Web of Science ®Google Scholar
• TORMANEN U, EEROLA A-K, RAINIO P et al.: Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma. Cancer Res. (1995) 55:5595–5002.
   PubMed Web of Science ®Google Scholar
• VAKKALA M, IÄHTEENMAKI K, RAUNIO P, PAAKKO P, SOINI Y: Apoptosis during breast carcinoma progres-sion. Clin. Cancer Res. (1999) 5:319–324.
   PubMed Web of Science ®Google Scholar
• SMETS LA: Programmed cell death (apoptosis) and response to anticancer drugs. AntiCancer Drugs (1994) 5:3–9:
   PubMed Web of Science ®Google Scholar
• MOSS SF, CALAM J, AGARWAL B, WANG S, HOLT PR: Induction of gastric epithelial apoptosis by Helico-bacter pylori. Gut (1996) 38:498–501.
   PubMed Web of Science ®Google Scholar
• SOINI V, VIRKAJARVI N, LEHTO V-P, PAAKKO P: Hepato-cellular carcinomas with a high proliferation index and a low degree of apoptosis and necrosis are associ-ated with a shortened survival. Br. J. Cancer (1996) 73:1025–1030.
   PubMed Web of Science ®Google Scholar
• COHEN JJ, DUKE RC: Glucocorticoid activation of a calcium dependant endonuclease in thymocyte nuclei leads to cell death. J. Immunol. (1984) 132:38–42.
   PubMed Web of Science ®Google Scholar
• MCCONKEY DJ, ORRENIUS S: Signal transduction pathways to apoptosis. Trends Cell Biol. (1994) 4:370–374.
   PubMedGoogle Scholar
• ALNEMRI ES, LITWACK G: Activation of internucleo-somal DNA cleavage in human CEN lymphocytes by glucocorticoid and novobiocin. Evidence for a non-calcium requiring mechanism(s). J. Biol. Chem. (1990) 265:17323–17333.
   PubMed Web of Science ®Google Scholar
• DUPREZ E, GJERSTEN BJ, BERNARD O, LANOTTE M, DOSKELAND SO: Anti-apoptotic effect of heterozy-gously expressed mutant RI (A1a336-Asp) subunit of cAMP kinase I in a rat leukemia cell line. J. Biol. Chem. (1993) 268:8332–8340.
   PubMedGoogle Scholar
• MCCONKEY DJ, ORRENIUS S, JONDAL M: Agents thatelevate cAMP stimulate DNA fragmentation in thymocytes. J. Immunol. (1990) 145:1227–1230.
   PubMed Web of Science ®Google Scholar
• TARTAGLIA L, AYRES T, WONG G, GOEDDEL D: A noveldomain within the 55 kD TNF receptor signals cell death. Cell (1993) 74:845–853.
   PubMed Web of Science ®Google Scholar
• MARTINS LM, EARNSHAW WC: Apoptosis: alive and kicking in 1997. Trends Cell Biol. (1997) 7:111–114.
   PubMed Web of Science ®Google Scholar
• DRESSLER KA, MATHIAS S, KOLESNICK RN: Tumor necrosis factor-a activates the sphingomyelin signal transduction pathway in a cell-free system. Science (1992) 255:1715–1718.
   PubMed Web of Science ®Google Scholar
• JAEVIS WD, KOLESNIK RN, FORNARI FA, TRAYLOR RS, GEWITZ DA, GRANT D: Induction of apoptotic DNA damage and cell death by activation of the sphingo-myelin pathway. Proc. Natl. Acad. Sci. USA (1994) 91:73–77.
   PubMed Web of Science ®Google Scholar
• MATHIAS S, PEO A, KOLESNIK N: Signal transduction ofstress via cerarnide. Biochem. J. (1998) 335:465–480.
   PubMed Web of Science ®Google Scholar
• YOSHIMURA S, BANNO Y, NAKASHIMA S et al.: Cerarnideformation leads to caspase-3 activation during hypoxic PC12 cell death. Inhibitory effects of Bc1-2 on ceramide formation and caspase-3 activation. J. Biol. Chem. (1998) 273:6921–6927.
   Google Scholar
• ZAMZANI N, MARCHETTI P, CASTEDO M et al.: Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J. Exp. Med. (1995) 181:1661–1672.
   PubMed Web of Science ®Google Scholar
• GALLAGER WM, BROWN R: p53-Oriented cancer therapies: Current progress. Ann. Oncol. (1999) 10:139–150.
   Web of Science ®Google Scholar
• •.A very stimulating review of the current knowledge of p53biology and its potential for the development of novel anticancer therapies.
   Google Scholar
• CAELLES C, HELMBERG A, KARIN M: p53-dependent apoptosis in the absence of transcriptional activation of p-53 target genes. Nature (1994) 370:220–223.
   PubMed Web of Science ®Google Scholar
• ORRENIUS S: Apoptosis: molecular mechanisms and implications for human disease. J. Intern. Med. (1995) 237:529–536.
   PubMed Web of Science ®Google Scholar
• ZYCHLINSKY A, SANSONETTI P: Apoptosis in bacterialpathogenesis. J. Clin. Invest. (1997) 100:493–496.
   PubMed Web of Science ®Google Scholar
• KHELEF N, ZYCHLINSKY A, GUISO N: Bordetella pertussis induces apoptosis in macrophages: role of adenylate cyclase-hemolysin. Infect. Immun. (1993) 61:4064–4071.
   PubMed Web of Science ®Google Scholar
• KHELEF N, GUISO N: Induction of macrophage apoptosis by Bordetella pertussis adenylate cyclase-hemolysin. FEMS Microbiol. Lett. (1995) 134:27–32.
   PubMed Web of Science ®Google Scholar
• FIORENTINI C, ARANCIA G, PARADISI S et al.: Effects ofClostridium difficile toxins A and B on cytoskeleton organisation in Hep-2 cells: a comparative morpho-logical study. Toxicon (1989) 27:1209–1218.
   PubMed Web of Science ®Google Scholar
• FIORENTINI C, FABRI A., FALZANO L et al.: Clostridiumdifficile toxin b induces apoptosis in intestinal cultured cells. Infect. Immun. (1998) 66:2660–2665.
   Google Scholar
• HENNING SV, GALANDRINI R, HALL A, CANTRELL DA:The GTPase Rho has a critical role in thymus develop-ment. EMBO J. (1997)16:2397–2407.
   PubMed Web of Science ®Google Scholar
• OLSON MF, ASHWORTH A, HALL A: An essential role for Rho, Rac and Cdc GTPases in cell cycle progression through Gi. Science (1995) 269:1271–1272.
   Google Scholar
• RAMAGOWDA B, SAMUEL JE, TESH VL: Interaction of Shiga toxins with human brain microvascular endothelial cells: cytokines as sensitizing agents. J. Infect. Dis. (1999) 180:1205–1213.
   PubMed Web of Science ®Google Scholar
• KIYOKAWA N, TAGUCHI T, MORI T et al.: Induction of apoptosis in normal human renal tubular epithelial cells by Ecsherichia coil Shiga Toxins 1 and 2.J. Infect Dis. (1998) 178:178–184.
   Google Scholar
• UCHIDA H, KIYOKAWA N, TAGUCHI T, HORIE H, FUJIMOTO J, TAKEDA T: Shiga toxins induce apoptosis in pulmonary epithelium-derived cells. J. Infect. Dis. (1999) 180:1902–1911.
   PubMed Web of Science ®Google Scholar
• ZANG C, AO Z, SEITH A, SCHLOSSMAN SF: A mitochon-drial membrane protein defined by a novel monoclonal antibody is preferentially detected in apoptotic cells. J. Immunol. (1996) 157:3980–3987.
   PubMed Web of Science ®Google Scholar
• MANGENEY M, LINGWOOD CA, TAGA S, CAILLOU B, TUSH T, WIELS J: Apoptosis induced in Burkitt's lymphoma cells via Gb3/CD77, a glycolipid antigen. Cancer Res. (1993) 53:5314–5319.
   PubMed Web of Science ®Google Scholar
• LINGWOOD CA: Verotoxins and their glycolipid receptors. Adv. Lip. Res. (1993) 25:189–212.
   PubMedGoogle Scholar
• DONOHUE-ROLFE A, KEUSCH GT, EDSON C, THORLEY-LAWSON D, JACEWICZ M: Pathogenesis of Shigella diarrhea. 1X. Simplified high yield purification of Shigella toxin and characterisation of subunit composition and function by the use of subunit-specific monoclonal and polyclonal antibodies./ Exp. Med. (1984) 160:1767–1781.
   Google Scholar
• ENDO Y, TSURUGI K, YUTSUDO T, TAKEDA Y, OGASAWARA T, IGARASHI K: Site of action of a Vero toxin (VT2) from Eschericbia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur. J. Biochem. (1988) 171:45–50.
   PubMedGoogle Scholar
• WILLIAMS JM, LEA N, LORD JM, ROBERTS LM, MILFORDDV, TAYLOR CM: Comparison of ribosome-inactivating proteins in the induction of apoptosis. Toxicol. Lett. (1997) 91:121–127.
   PubMed Web of Science ®Google Scholar
• KAYE SA et al.: Shiga toxin-associated hemolyticuremic syndrome: Interleukin-lb enhancement of Shiga toxin cytotoxicity toward human vascular endothelial cells in vitro. Infect. Immun. (1993) 61:3886–3891.
   PubMed Web of Science ®Google Scholar
• POLUNOVSKY VA, WENDT CH, INGBAR DH, PETERSON MS, BITTERMAN PB: Induction of endothelial cell apoptosis by TNF-a: modulation by inhibitors of protein sysnthesis. Exp. Cell Res. (1994) 214:584–594.
   PubMed Web of Science ®Google Scholar
• TOMB J-F, WHITE O, KERLAVAGE AR et al.: The complete genome sequence of the gastric pathogen Helico-bacter pylori. Nature (1997) 388:539–547.
   PubMed Web of Science ®Google Scholar
• BLASER MJ: Helicobacter pylori, the pathogenesis of gastroduodenal inflammation. Infect. Dis. (1990) 161:626–633.
   Google Scholar
• ESLICK GD, LIM LL, BYLES JE, XIA HH, TALLEY NJ:Association of Helicobacter pylori infection with gastric carcinome: a meta analysis. Am.J. Gastroenterol. (1999) 94:2373–2379.
   PubMed Web of Science ®Google Scholar
• SHIRIN H, SORDILLO EM, DELOHERY T, HOLT PR, WEINSTEIN IB, MOSS SF: Effect ofH. pylori on cell cycle progression, apoptosis, signal transduction in the AGS human gastric carcinoma cell line. Am. Assoc. Cancer Res. (1998) Abstract 11.
   Google Scholar
• TSUJI S, KAWANO S, TAKEI Y et al.: Ammonia induces gastric cell apoptosis: possible implication to Helicobacter-related gastric mucosal atrophy. Gastro-enterology (1995) 108:A244.
   Web of Science ®Google Scholar
• CHEN G, SORDILLO EM, RAMEY WG et al.: Apoptosis in gastric epithelial cells is induced by Helicobacter pylori, accompanied by increased expression of BAK. Biochem. Biophys. Res. Comm. (1997) 239:626–632.
   PubMed Web of Science ®Google Scholar
• PIOTROWSKI J: Lipopolysaccharide a virulence factor of Helicobacter pylori: effect of antiulcer agents. J. Physiol. Pharmacol. (1998) 49:3–24.
   PubMed Web of Science ®Google Scholar
• YAMAGUCHI H, OSAKI T, TAGUCHI H, HANAWA T, YAMAMOTO T, KAMIYA S: Flow cytometric analysis of the heat shock protein 60 expressed on the cell surface of Helicobacter pylori. J. Med. Microbiol. (1996) 45:270–277.
   PubMed Web of Science ®Google Scholar
• PAPINI E, SATIN B, BUCCI C, BERNARD MD et al.: Thesmall GTP-binding protein rab7 is essential for cellular vacuolation induced by H. pylori cytotoxin. EMBO j (1997) 16:15–24.
   PubMed Web of Science ®Google Scholar
• LIN YL, LIU JS, CHEN KT, CHEN CT, CHAN EC: Identifica-tion of neutral, acidic sphingomyelinases in Helico-bacter pylori. FESS Lea. (1998) 423:249–253.
   PubMed Web of Science ®Google Scholar
• SMOOT DT: How does Helicobacter pylori cause mucosal damage? Direct mechanisms. Gastroenterology (1997) 113:S31–S34.
   PubMed Web of Science ®Google Scholar
• FILION MC, LEPICIER P, MORALES A, PHILLIPS NC:Mycobacterium pblei cell wall complex directly induces apoptosis in human bladder cancer cells. Br.J. Cancer (1999) 79:221–228.
   PubMedGoogle Scholar
• FILION MC, LEPICIER P, PHILLIPS NC: Mycobactenumpblei cell wall complex, a new anti-tumor agent, induces IL-I 2 synthesis by monocytes/macrophages. Blood (1997) 90:58b.
   PubMedGoogle Scholar
• MILLER T, BEAUSANG LA, MENEGHINI M, LIDGARD G: Death-induced changes to the nuclear matrix: the use of anti-nuclear matrix antibodies to study agents of apoptosis. Biotechniques (1993) 15:1042–1047.
   PubMed Web of Science ®Google Scholar
• ZITVOGEL L, LOTZE MT: Role of IL- 12 as an anti-tumour agent: experimental biology, clinical applications. Immunol. Res. (1995) 146:628–638.
   Google Scholar
• SHAW GM, HAHN BH, ARAYA SK, GROOPMAN JE, GALLORC, WONG-STAAL F: Molecular characterisation of human T-cell leukemia (lymphotropic) virus Type BI in the acquired immune deficiency syndrome. Science (1984) 226:1165–1171.
   PubMed Web of Science ®Google Scholar
• MENZIZ B, KOURTEVA I: Internalisation of Staphylo-coccus aureus by endothelial cells induces apoptosis. Infect. Immun. (1998) 66:5994–5998.
   PubMed Web of Science ®Google Scholar
• VANN JM, PROCTOR RA: Cytotoxic effects of ingested S. aureus on bovine endothelial cells: role of S. aureus a-hemolysin. Microb. Pathog. (1988) 4:443–453.
   Google Scholar
• ROULSTON A, MARCELLUS RC, BRANTON PE: Viruses and apoptosis. Ann. Rev. Microbiol. (1999) 3:577–628.
   Google Scholar
• •A valuable review about dynamic relation between viral replication and defensive host response which often results in host cell apoptosis. The apoptotic characteristics of a large number of viral agents are discussed.
   Google Scholar
• CASTELLI JC, HASSEL BA, WOOD KA et al.: A study of theinterferon antiviral mechanism: apoptosis activation by the 2-5A system. J. Exp. Med. (1997) 186:967–972.
   PubMed Web of Science ®Google Scholar
• TANAKA N, SATO M, LAMPIER MS et al.: Type I interferons are essential mediators of apoptotic death in virally infected cells. Genes Cells (1998) 3:9–37.
   PubMedGoogle Scholar
• MAHALINGAM S, AYYAVO0 V, PATEL M, KIEBER-EMMONS T, WEINER D: Nuclear Import, virion incorpo-ration and cell cycle arrest/differentiation are mediated by distinct functional domains of human immunodeficiency virus Type 1 Vpr. J.Virol. (1997) 71:6339–6347.
   PubMed Web of Science ®Google Scholar
• MAHALINGAM S, MACDONALD B, UGEN KE eta/.: In vitro and In vivo Tumor Growth Suppression by HIV-1 Vpr. DNA Cell Biology (1997) 16:137–143.
   Google Scholar
• HEIZINGER N, BUKRINSKY M, HAGGERTY S et al.: The HIV-1 Vpr protein influences nuclear targeting of viral nuclear acids in non-dividing cells. Proc. Natl. Acad. Sci. USA (1994) 91:7311–7315.
   PubMedGoogle Scholar
• STIVANTIS GL, SOARES MA, VODICKA MA, HAHN BH, EMERMAN M: Concervation and host specificity of Vpr-mediated cell cycle arrest suggest a fundamental role in primate lentivirus evolution and biology. J. Virol. (1997) 71:4331–4338.
   PubMed Web of Science ®Google Scholar
• ROGEL M, WU L, EMERMAN M: The human immunodefi-ciency virus Type 1 vpr gene prevents cell prolifera-tion during chronic infection. J. Virol. (1995) 69:882–888.
   PubMed Web of Science ®Google Scholar
• STEWART SA, POON B, JOWETT JB, XIE Y, CHEN SY: Lentiviral delivery of HIV-1 Vpr protein induces apoptosis in transformed cells. Proc. Natl. Acad. Sci. USA (1999) 96:12039–12043.
   PubMed Web of Science ®Google Scholar
• MORTON DL, FOSHAG 41, HOON SB et al.: Prolongation of survival in metastatic melanoma after specific irnmunotherapy with a new polyvalent melanoma vaccine. Ann. Surg. (1992) 216:463–483.
   Google Scholar
• MACREADIE IG, CASTELLI LA, HEWISH DR, KIRKPATRICK A, WARD AC, AZAD AA: A domain of human immunode-ficiency virus Type 1 Vpr contains repeated H(S/F)RIG amino acid motifs causes cell growth arrest and structural defects. Proc. Natl. Acad. Sci. USA (1995) 92:2770–2774.
   PubMed Web of Science ®Google Scholar
• MACREADIE IG, ARUNAGIRI CK, HEWISH DR, WHITE JF,AZAD AA: Extracellular addition of a domain of HIV-1 Vpr containing the amino acid sequence motief H(S/F)RIG causes cell membrane pernieabilisation and death. Mol. Micro biol. (1996) 19:1185–1192.
   PubMed Web of Science ®Google Scholar
• DANEN-VAN OORSCHOT AA, FISCHER DF, GRIMBERGENJM et al.: Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells. Proc. Natl. Acad. Sci. USA (1997) 94:5843–5847.
   PubMed Web of Science ®Google Scholar
• ZUANG SM, SHWARTS A, VAN ORMONDT H et al.: Apoptin, a protein derived from chicken anemia virus, induces p53-independent apoptosis in human osteosarcoma cells. Cancer Res. (1995) 55:486–89.
   Google Scholar
• PASECHNIK V, PRICE J: Macromolecular drug deliverywith protein carriers. Exp. Opin. Invest. Drugs (1996) 5:1255–1276.
   Google Scholar
• LODE HN, XIANG R, DUNCAN SR, THEOFILOPOULOS AN,GILLIES SD, REISFELD RA: Tumor-targeted IL-2 amplifies T-cell -mediated immune response induced by gene therapy with single-chain IL-12. Proc. Natl. Acad. Sci. USA (1999) 96:8591–8596.
   PubMed Web of Science ®Google Scholar
• MCCALL AM, ADAMS GP, AMOROSO AR et al.: Isolationand characterisation of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/ anti-CD16 bispecific scEv that triggers CD16 -depen-dent tumor cytolisis. Molec. Immunol.(1999) 36:433–445.
   PubMed Web of Science ®Google Scholar
• PAGNAN G, MONTALDO PG, PASTORINO F et al.: GD2-mediated melanoma cell targeting and cytotox-icity of liposome-entrapped fenretinide. Int. J. Cancer (1999) 81:268–274.
   PubMed Web of Science ®Google Scholar
• HAN JS, NUNEZ G, WICHA MS, CLARKE MF: Targeting cancer cell death with a lbc1-xs adenovirus. Springer Semin. Immunopathol. (1998) 19:279–288.
   PubMed Web of Science ®Google Scholar
• NAGAHARA H, VOCERO-AKBANI AM, SNYDER EL et al.: Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p271GP1 induces cell migration. Nature Med. (1998) 4:1449–1452.
   PubMed Web of Science ®Google Scholar
• FRANKEL AD, PABO CO: Cellular uptake of the TATprotein from human immunodeficiency virus. Cell (1988) 55:1189–1193.
   PubMed Web of Science ®Google Scholar
• FAWELL S, SEERY, DAIKH Y et al.: Tat-mediated deliveryof heterogeneous proteins into cells Proc. Natl. Acad. Sci. USA (1994) 91:664–668.
   PubMed Web of Science ®Google Scholar
• ARAP W, PASQUALINI R, RUOSLAHTI E: Cancer treatment by targeted drug delivery to tumor vascula-ture in a mouse model Science (1998) 279:377–380.
   Google Scholar
• PAN CX, KOENEMAN KS: A novel tumor-specific genetherapy for bladder cancer. Med. Hypothesis (1999) 53(2):130435.
   Google Scholar
• VASEY PA, KAYE SB, MORRISON R et al.: Phase I clinicaland pharmacokinetic study of pkl [n-(2-hydro xypropyl)methacrylarnide copolymer doxorubicia first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin. Cancer. Res. (1999) 5:83–94.
   PubMed Web of Science ®Google Scholar
• LOW KB, ITTENSOHN M, LE T et al.: Lipid A mutant Salmonella with suppressed virulence, TNFa induction retain tumor-targeting in vivo. Nature Biotechnol. (1999) 17:37–41.
   PubMed Web of Science ®Google Scholar
• SHTRICHMAN R, SHARF R, BARR H, DOBNER T, KLEINBERGER T: Induction of apoptosis by adenovirus E4orf4 protein is specific to transformed cells, requires an interaction with protein phosphatese 2A. Proc. Natl. Acad. Sci. USA (1999) 96:10080–10085.
   PubMed Web of Science ®Google Scholar
• YU D-C, CHEN Y, SENG M, DILLEY J, HENDERSON DR: The addition of adenovirus Type 5 region E3 enables Calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res. (1999) 59:4200–4203.
   PubMed Web of Science ®Google Scholar
• COFFEY MC, STRONG GE, FORSYTH PA, LEE PWK: Reovirus therapy of tumors with activated ras pathway. Science (1998) 282:1332–1334.
   PubMed Web of Science ®Google Scholar
• STRONG JE, COFFEY MC, TANG D, SABININ P, LEE PKW: The molecular basis of viral oncolysis: usurpation of the Ras signalling pathway by reoviruses. EMBO J. (1998) 17:3351–3362.
   PubMed Web of Science ®Google Scholar
• SMAGLIK P: Biotech firms on quest for apoptotic therapies. The Scientist 1998 12:6.
   Google Scholar
• SHERIDAN et al.: Control of TRAIL-induced apoptosis by a family of signaling, decoy receptors. Science (1997) 277:818–821.
   PubMed Web of Science ®Google Scholar
• PIAZZA et al.: Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest and p53 induction. Cancer Res. (1997) 57:2452–2459.
   PubMed Web of Science ®Google Scholar
• VOCERO-AKBANI AM, HEYDEN NV, LISSY NA, RATNER L, DOWDY SF: Killing HIV-infected cells by transduction with a HIV protease-activated caspase-3 protein. Nature Med. (1999) 5:29–33.
   PubMed Web of Science ®Google Scholar
• TAN Y, ZAVALA J Sr, HAN Q et al.: Recombinant methioninase infusion reduces the biochemical endpoint. of serum methionine with minimal toxicity in high-stage cancers. AntiCancer Res. (1997) 17:3857–3860.
   Google Scholar
• DOGGWEILER R, ZERMANN D-H, ISHIGOOKA M, SCHNIDT RA: Bottox-induced Prostatic involution in prostate. Prostate (1998) 37:44–50.
   PubMed Web of Science ®Google Scholar
• WILLIAMS MD, ROSTOVTSEV A, NARLA RK, UKUN FM: Production of recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system for biother-apy of GMCSF-receptor positive hematological malignancies. Prot. Exp. Purif (1998) 13:201–204.
   Google Scholar
• BONN D: Targeting protein breakdown to treat cancer cells. Mol. Med. Today (1999):48–49.
   PubMedGoogle Scholar
• PIETERSEN AM, VANORMOND H, MASMAN D et al.: Specific tumor-cell killing with adenovirus vectors containing the apoptin gene. Gene Ther. (1999) 6:882–892.
   PubMedGoogle Scholar
• HOFFMAN RM: Methioninase: a Therapeutic for Diseases Related to altered Methionine Metabolism and Transmethylation: Cancer, Heart Disease, Obesity, Ageing and Parkinson's disease. Human Cell (1997) 10:69–82.
   PubMedGoogle Scholar
• HOFFMAN B, LIEBERMAN DA: Molecular control of apoptosis: differentiation/growth arrest primary responce genes, proto-oncogenes and tumor suppressor genes as positive and negative modulators. Oncogene (1994) 9:1807–1812.
   PubMed Web of Science ®Google Scholar
• DIXON SC, ARAH IN: Apoptosis: a novel therapeutic tool. Exp. Opin. Invest. Drugs (1998) 7:889–904.
   PubMedGoogle Scholar
• •A good review about mechanisms of apoptosis induction during several anticancer treatments such as chemotherapy, cytokine-mediated therapy, radiation therapy and genetic approaches. The possibility of increasing the sensitisation of drug-resistant tumour cells using genetic modification is also discussed.
   Google Scholar
• MARTIN SJ: Apoptosis and cancer. Karger Landes, Basel, Switzerland (1997).
   Google Scholar
• •A comprehensive review on the relation between apoptosis and cancer. It also covers apoptosis in specific tumours such as prostate cancer, kidney, renal neoplasms, leukaemias, neuroblastoma tumours. Potential therapeutic implications of modulating apoptosis are considered.
   Google Scholar
• THOMPSON CB: Apoptosis in the pathogenesis and treatment of disease. Science (1995) 267:1456–1462.
   PubMed Web of Science ®Google Scholar
• KATO Y, SUGIYAMA Y: Targeted delivery of peptides, proteins and genes by receptor-mediated endocytosis. Crit Rev. Ther. Drug Carrier Syst. (1997) 14:287–331.
   PubMed Web of Science ®Google Scholar
• LANGER M, KRAL TE: Liposome-based drug delivery systems. Pol. J. Pharmacol. (1999) 51:211–222.
   PubMedGoogle Scholar
• SMITH AE: Viral vectors in gene therapy. Ann. Rev. Microbiol. (1995) 49:807–838.
   PubMed Web of Science ®Google Scholar
• KOGA H, INAMURA T, IKEZAKI K, SAMOTO K et al.: Selective transvascular delivery of oligonucleotides to experimental brain tumors. J. Neurooncol. (1999) 43:143–151.
   PubMed Web of Science ®Google Scholar
• COCHET O, KENIGSBERG M, DELUMEAU I et al.: Intracel-lular expression of an antibody fragment-neutralising p21 ras promotes tumor regression. Cancer Res. (1998) 58:1170–1176.
   PubMed Web of Science ®Google Scholar
• MORI S, MURAKAMI-MORI K, NAKAMURA S, ASHKENAZI A, BONAVIDA B: Sensitization of AIDS-Kaposi's sarcoma cells to Apo-2 ligand-induced apoptosis by actinomycin. J. Immunol. (1999) 162:5616–5623.
   PubMed Web of Science ®Google Scholar
• GRIFFITH TS, CHIN WA, JACKSON GC, LYNCH DH, KUBIN MZ: Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells./ Immunol. (1998) 161:2833–2840.
   PubMed Web of Science ®Google Scholar
• UENO NT, BARTHOLOMEUSZ C, HERRMANN JL et al.: E1A-mediated paclitaxel sensitisation in HER-2/neu-overexpressing ovarian cancer SKOV3.ipl through apoptosis involving the caspase-3 pathway. Clin. Cancer Res. (2000) 6:250–259.
   Google Scholar